ClinicalTrials.gov
ClinicalTrials.gov Menu

The Origin of Infrapyloric Artery (IPA-Origin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03071237
Recruitment Status : Recruiting
First Posted : March 6, 2017
Last Update Posted : March 6, 2017
Sponsor:
Information provided by (Responsible Party):
Jiafu Ji, Peking University

Brief Summary:
Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies. This trial aims to tell the distribution of IPA origin in Chinese patients.

Condition or disease Intervention/treatment
Stomach Neoplasm Procedure: Gastrectomy

Detailed Description:

Infrapyloric artery(IPA) is of great importance for gastric cancer patients. In early gastric cancer patients, the pylorus-preserving gastrectomy requires the preserving of IPA. In advanced gastric cancer patients, the subgroup of No. 6 lymph node might be associated with IPA. In JGCA gastric cancer classification guidelines, the No. 6 lymph nodes is defined as lympn nodes along the first branch and proximal part of the right gastroepiploic artery(RGEA) down to the confluence of the right gastroepiploic vein and the anterior superior pancreatoduodenal vein. However,if IPA origins from the gastroduodenal artery(GDA) or anterior superior pancreatoduodenal artery(ASPDA), the lymph nodes along the IPA can not be grouped into the No. 6 lymph nodes. Thus, a new definition of No. 6 lymph nodes is needed on the basis of the origin of IPA.

Previous studies about IPA origin are few and the origin of IPA varies greatly among different studies.


Study Type : Observational
Estimated Enrollment : 442 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Origin of Infrapyloric Artery: an Observational Trial
Estimated Study Start Date : March 4, 2017
Estimated Primary Completion Date : December 31, 2017
Estimated Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer
U.S. FDA Resources

Group/Cohort Intervention/treatment
Observational group
Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photoed or video-recorded before its transection.
Procedure: Gastrectomy
Paitents with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
Other Name: surgery



Primary Outcome Measures :
  1. Distribution of IPA origin [ Time Frame: Immediately after surgery ]
    The percentage of IPA origin from GDA, ASPDA and RGEA.


Secondary Outcome Measures :
  1. Reconstruction rate of IPA by CT scan [ Time Frame: Immediately after the reconstruction of CT scan. ]
    The rate of identification of IPA origin by reconstruction of CT scan.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Patients with gastric cancer who needs to receive total or distal gastrectomy.
Criteria

Inclusion Criteria:

  • Patients with gastric cancer who needs to receive total or distal gastrectomy.
  • Signed informed consent

Exclusion Criteria:

  • IPA not dissected, photoed or video-recorded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03071237


Contacts
Contact: Rulin Miao, M.D. 86-10-88196598 miaorulin@outlook.com

Locations
China, Beijing
Beijing Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Contact: Rulin Miao, M.D.    86-10-88196598    miaorulin@outlook.com   
Principal Investigator: Ziyu Li, M.D.         
Sub-Investigator: Rulin Miao, M.D.         
Sponsors and Collaborators
Peking University
Investigators
Principal Investigator: Ziyu Li, M.D. Gastrointestinal Cancer Center, Peking University

Publications:
Responsible Party: Jiafu Ji, MD, Peking University
ClinicalTrials.gov Identifier: NCT03071237     History of Changes
Other Study ID Numbers: 2017YJZ07
First Posted: March 6, 2017    Key Record Dates
Last Update Posted: March 6, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jiafu Ji, Peking University:
infrapyloric artery
gastric cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases